Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Macular Neovascularization Secondary to Age-Related Macular Degeneration: later-stage trial registry
1 of 1 indexed Macular Neovascularization Secondary to Age-Related Macular Degeneration trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Macular Neovascularization Secondary to Age-Related Macular Degeneration: 1 US clinical trial tracked, 1 recruiting.
Macular Neovascularization Secondary to Age-Related Macular Degeneration is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is 4D Molecular Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition macular-neovascularization-secondary-to-age-related-macular-degeneration
OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Macular Neovascularization Secondary to Age-Related Macular Degeneration lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Macular Neovascularization Secondary to Age-Related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Macular Neovascularization Secondary to Age-Related Macular Degeneration is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Macular Neovascularization Secondary to Age-Related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Macular Neovascularization Secondary to Age-Related Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Macular Neovascularization Secondary to Age-Related Macular Degeneration page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Macular Neovascularization Secondary to Age-Related Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- 4D Molecular Therapeutics sponsors the most Macular Neovascularization Secondary to Age-Related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See 4D Molecular Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Macular Neovascularization Secondary to Age-Related Macular Degeneration condition card totals 1 registered trials; most-linked intervention EYLEA® (aflibercept) Injection 2 mg (0.05mL); top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.